Evidence map›Paper›PMID 41126834›Full record

ArticleFrontiers in immunology2025

Clinical and immunological spectrum of MHC class I deficiency: insights from a long-term cohort with two novel mutations.

Sule Haskologlu, Aydan Ikinciogullari, Candan Islamoglu, Sevgi Kostel Bal, Deniz Bayrakoglu, Serife Erdem, Zeynep Ceren Karahan, Omur Ardeniz, Caner Aytekin, Aylin Heper and 2 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sule HaskologluFaculty of Medicine, Department of Pediatric Immunology and Allergy, and Hematopoietic Stem Cell Transplantation Unit, Ankara University, Ankara, Türkiye.
Aydan IkinciogullariFaculty of Medicine, Department of Pediatric Immunology and Allergy, and Hematopoietic Stem Cell Transplantation Unit, Ankara University, Ankara, Türkiye.
Candan IslamogluFaculty of Medicine, Department of Pediatric Immunology and Allergy, and Hematopoietic Stem Cell Transplantation Unit, Ankara University, Ankara, Türkiye.
Sevgi Kostel BalDepartment of Pediatric Immunology and Allergy, Gülhane Training and Research Hospital, Ankara, Türkiye.
Deniz BayrakogluFaculty of Medicine, Department of Pediatric Immunology and Allergy, and Hematopoietic Stem Cell Transplantation Unit, Ankara University, Ankara, Türkiye.
Serife ErdemBetul-Ziya Eren Genome and Stem Cell Center, Erciyes University, Kayseri, Türkiye.
Zeynep Ceren KarahanFaculty of Medicine, Department of Medical Microbiology, Ankara University, Ankara, Türkiye.
Omur ArdenizFaculty of Medicine, Department of Internal Medicine, Division of Allergy and Immunology, Ege University, Izmir, Türkiye.
Caner AytekinDepartment of Pediatric Allergy and Immunology, Dr. Sami Ulus Children's Health and Diseases Training and Research Hospital, Ankara, Türkiye.
Aylin HeperFaculty of Medicine, Department of Medical Pathology, Ankara University, Ankara, Türkiye.
Serdar CeylanerIntergen Genetics and Rare Diseases Diagnosis Research & Application Center, Ankara, Türkiye.
Figen DoguFaculty of Medicine, Department of Pediatric Immunology and Allergy, and Hematopoietic Stem Cell Transplantation Unit, Ankara University, Ankara, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Major histocompatibility complex (MHC) Class I deficiency is a rare form of primary immunodeficiency that typically presents with recurrent sinopulmonary infections, bronchiectasis, and granulomatous skin lesions during late childhood or adolescence. Methods: This retrospective study describes the clinical, immunological, and long-term follow-up data of 11 patients diagnosed MHC Class I deficiency. Results: The cohort included 11 patients (6 males, 5 females) with a median age of 26 years (range 19-44). The median age at diagnosis was 19 years, with a diagnostic delay of 14 years. Bronchiectasis was seen in 10 patients, granulomatous skin lesions in 6, uveitis in 5, and nasal septum perforation in 3. All but one patient survived during a median follow-up of 11 years. HLA-ABC expression ranged from 0% to 73%, with persistently low mean fluorescence intensity (0.4-3.8). IgM levels were reduced in 7 patients. Ten patients were persistently positive for anti-rubella IgM, including all six with granulomatous skin lesions. Immunophenotyping revealed reduced CD3 Conclusion: MHC Class I deficiency presents a broad clinical spectrum from asymptomatic to life-threatening disease. Granulomatous tissue damage and uveitis contributed to morbidity. Persistent rubella-specific IgM in most patients, including those without granulomas, is a novel serologic finding that may reflect altered antiviral immunity. Its clinical significance remains uncertain and, further studies with tissue-based viral detection are needed to clarify this observation.

Indexed as

Histocompatibility Antigens Class IMutationAdultFemaleHumansImmunophenotypingMaleRetrospective StudiesYoung AdultHistocompatibility Antigens Class Ianti-rubella IgM positivityfollow-upgranulomatous skin lesionsMHC class I deficiencyuveitis

Identifiers

PMID41126834
PMCPMC12537883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.